Lingbo Biotech Secures Tens of Millions of RMB in Series A+ Financing to Advance Regenerative Medicine Pipeline

On June 12, 2024, LEADBIO (Hangzhou) Co., Ltd. ("LEADBIO") completed a multi-million yuan A+ round of financing invested by Hangzhou Tianshili New Racetrack Equity Investment Partnership (Limited Partnership). This is a new round of financing completed by LEADBIO in a short time after the completion of the A round at the end of 2023.

The funds from this round of financing will be mainly used for the clinical advancement of existing products and the research and development of new indications for coronary artery bypass artificial blood vessels, accelerating the progress of multiple preclinical studies and promoting LEADBIO's research and innovation in the field of regenerative medicine.

LEADBIO was founded in February 2019, adhering to the mission of "Applying Technology, Innovating Healthcare." It is committed to the research and development of tissue-engineered artificial organs and organ preservation products that can replace and repair human tissues and organs, aspiring to become a global leader in regenerative medicine R&D and manufacturing. Upholding the vision of "Innovating for Life," LEADBIO will fully utilize this round of financing to accelerate product development, clinical trials, and market expansion, providing more and better tissue-engineered artificial organs and organ preservation products for patients worldwide.